Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Japanese drugmaker Takeda cuts full-year loss forecast

Takeda Pharmaceutical Co. trimmed the company’s full-year fiscal 2019 loss forecast on strong sales of core drugs and progress in consolidating with Shire Plc.

Read More »

Kala Pharmaceuticals Receives FDA CRL for KPI-121 0.25% NDA

Kala Pharmaceuticals Inc. received a complete response letter from the U.S. Food and Drug Administration regarding the company’s new drug application for KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.

Read More »

Allergan beats profit; raises 2019 revenue forecast on Restasis, Juvederm demand

Allergan Plc – which is being bought by AbbVie Inc. for $63 billion – beat second-quarter 2019 profit estimates and raised the company’s full-year revenue forecast, helped by demand for the dry eye drug Restasis and aesthetics product Juvederm.

Read More »

Novartis buys dry-eye drug from Takeda for up to $5.3 billion

Novartis is buying the projected blockbuster dry-eye drug Xiidra from Takeda Pharmaceutical for up to $5.3 billion.

Read More »

Kala Pharmaceuticals’s NDA for KPI-121 0.25% for Dry Eye Disease Accepted for FDA Review

Kala Pharmaceuticals Inc. announced that the New Drug Application (NDA) for KPI-121 0.25%, a product candidate for the temporary relief of signs and symptoms of dry eye disease utilizing a two-week course of therapy, has been accepted for review by the United States Food and Drug Administration FDA.

Read More »

Allergan Backs off From $200 Million Plant Expansion in Waco, Texas

Dublin-based Allergan announced in 2016 plans to spend $200 million to expand the company’s manufacturing facility in Waco, Texas. That plan would have increased production capacity by more than 50 percent and created more than 100 jobs in the area.

Read More »

FDA approves Kala Pharma’s eye pain drug

The U.S. Food and Drug Administration approved Kala Pharmaceuticals Inc.’s treatment for reducing inflammation and pain following an eye surgery.

Read More »

U.S. FDA Approves Sun Pharmaceuticals’ Cequa

Sun Pharmaceutical Industries Ltd. received FDA approval for Cequa (cyclosporine ophthalmic solution) 0.09% to increase tear production in patients with keratoconjunctivitis sicca.

Read More »

U.S. court rejects Allergan bid to shield patents through tribe deal

A U.S. appeals court rejected a novel strategy adopted by drug company Allergan to shield patents from review by an administrative court by transferring them to a Native American tribe.

Read More »

Walgreen, Kroger, Albertsons, HEB sue Allergan over dry-eye drug

Allergan Inc. was sued by four large U.S. retailers that accused the drugmaker of antitrust violations for trying to stop rivals from selling generic versions of Restasis, the company’s medication to treat dry-eye disease.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom